Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 481
interventional 447
Observational 33
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 201
Drug|Radiation 53
Biological 30
Biological|Drug 23
Drug|placebo 18
Other 17
Drug|Other 11
Radiation 10
Drug|Procedure 9
Drug|Procedure|Radiation 7
Biological|Other 6
Drug|Other|Radiation 5
Procedure 5
Behavioral 4
Biological|Drug|Other 4
Biological|Drug|Radiation 4
Device|Drug 3
Diagnostic Test 3
Drug|Other|Procedure 3
Other|Procedure 3
Combination Product 2
Combination Product|Drug 2
Dietary Supplement 2
Dietary Supplement|placebo 2
Procedure|Radiation 2
Behavioral|Drug|placebo 1
Behavioral|Other 1
Biological|Diagnostic Test 1
Biological|Drug|Other|placebo 1
Biological|Drug|Other|Radiation 1
Biological|Drug|placebo|Radiation 1
Biological|Drug|Procedure 1
Biological|Drug|Procedure|Radiation 1
Biological|Genetic 1
Biological|Other|Procedure|Radiation 1
Biological|Other|Radiation 1
Biological|placebo 1
Biological|Radiation 1
Device|Diagnostic Test 1
Device|Drug|Radiation 1
Drug|Other|placebo 1
Drug|Other|placebo|Radiation 1
Drug|placebo|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 226
France 28
China 22
Canada 11
NA 11
United States|Canada 10
Germany 9
Korea, Republic of 6
Netherlands 6
Denmark 4
Italy 4
Spain 4
Taiwan 4
Brazil 3
United Kingdom 3
Belgium 2
France|Germany|Spain 2
India 2
Japan 2
Switzerland 2
United States|Australia 2
United States|France|Germany|Spain 2
United States|France|Spain 2
Argentina|Cuba|India|Indonesia|Pakistan|Philippines|South Africa|Thailand|Uruguay 1
Australia 1
Australia|Belgium|China|Germany|Japan|Singapore|Spain 1
Australia|Cuba|Egypt|India|Indonesia|Korea, Republic of|Malaysia|Philippines|Saudi Arabia|Singapore|South Africa|Taiwan|Thailand 1
Australia|Russian Federation 1
Austria 1
Austria|Belgium|Czech Republic|France|Germany|Hungary|Italy|Netherlands|Poland|Portugal|Russian Federation|Slovakia|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
Bangladesh 1
Belgium|France|Germany 1
Belgium|France|Italy|United Kingdom 1
Belgium|France|Netherlands|Switzerland 1
Belgium|Hungary|Slovakia|United Kingdom 1
Belgium|Italy 1
Belgium|Luxembourg 1
China|Korea, Republic of 1
Denmark|Sweden 1
Egypt 1
Finland 1
France|Greece|India|Peru|Spain 1
France|Italy|Netherlands|Spain|United Kingdom 1
France|Monaco 1
France|Spain 1
France|Switzerland 1
France|United Kingdom 1
Germany|United States|Australia|Austria|Brazil|France|Greece|Ireland|Israel|Italy|Japan|Korea, Republic of|Mexico|Poland|Spain|Switzerland|Taiwan|United Kingdom 1
Greece 1
Japan|Korea, Republic of 1
Lithuania 1
Mexico 1
Norway 1
Pakistan 1
Palestinian Territory, occupied 1
Poland 1
Singapore 1
Spain|United States|Belgium|Germany|Italy|United Kingdom 1
Thailand 1
United Kingdom|United States|Belgium|Denmark|Sweden 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Colombia|France|Germany|Hungary|Israel|Japan|Korea, Republic of|Poland|Portugal|Russian Federation|Spain|Switzerland|Taiwan|Ukraine|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Chile|Croatia|Czechia|France|Georgia|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Poland|Romania|Russian Federation|Serbia|Spain|Taiwan|Ukraine 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Croatia|Czech Republic|Estonia|Greece|India|Israel|Italy|Latvia|Lithuania|Malaysia|Netherlands|Norway|Russian Federation|Slovenia|South Africa|Spain|Sweden|Thailand|United Kingdom 1
United States|Argentina|Australia|Canada|Chile|France|Germany|Hong Kong|Hungary|Italy|New Zealand|Poland|Singapore|South Africa|Spain|Switzerland|Taiwan 1
United States|Argentina|Australia|Canada|France|Germany|Greece|Ireland|Israel|Korea, Republic of|Netherlands|Norway|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|Taiwan|United Kingdom 1
United States|Argentina|Belgium|Brazil|Canada|Chile|Czechia|Finland|France|Ireland|Italy|Mexico|Netherlands|Norway|Romania|Russian Federation|South Africa|Spain|Sweden|Turkey|United Kingdom 1
United States|Argentina|Brazil|Canada|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Spain|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Canada|Colombia|Czechia|France|Germany|Israel|Italy|Japan|Korea, Republic of|Netherlands|New Zealand|Poland|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|France|Greece|Italy|Spain|Switzerland|United Kingdom 1
United States|Australia|Austria|Belgium|Denmark|Germany|Greece|Italy|Korea, Republic of|Malaysia|Netherlands|Norway|Spain|Taiwan|Thailand|United Kingdom 1
United States|Australia|Austria|Canada|Turkey|Hungary|Italy|Japan|Korea, Republic of|Poland|Portugal|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|China|France|Germany|Hungary|India|Italy|Japan|Korea, Republic of|Poland|Portugal|Russian Federation|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Australia|Belgium|Bulgaria|France|Germany|Hungary|Italy|Romania|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|France|Georgia|Germany|Hungary|Israel|Korea, Republic of|Malaysia|Spain|Taiwan|United Kingdom 1
United States|Australia|France|Italy|Japan 1
United States|Australia|Korea, Republic of|Taiwan 1
United States|Australia|Spain|United Kingdom 1
United States|Austria|Belgium|Brazil|Canada|France|Germany|Greece|India|Italy|Japan|Korea, Republic of|Philippines|Poland|Romania|Russian Federation|Slovakia|Spain|Taiwan|Thailand|Ukraine|United Kingdom|Vietnam 1
United States|Austria|Belgium|Czechia|France|Lithuania|Puerto Rico|Slovakia|Spain 1
United States|Austria|Israel|Korea, Republic of|Norway|Spain 1
United States|Belgium 1
United States|Belgium|Canada|Czechia|France|Georgia|Germany|Hungary|Israel|Korea, Republic of|Malaysia|Spain|Taiwan|United Kingdom 1
United States|Belgium|Canada|Italy|Poland|Spain 1
United States|Belgium|Canada|Spain 1
United States|Belgium|Czech Republic|France|Hungary|Poland|Slovakia|United Kingdom 1
United States|Belgium|Czech Republic|Germany|India|Poland|Serbia|Taiwan 1
United States|Bulgaria|Hungary|Romania 1
United States|Canada|France|Germany|Italy|Spain|United Kingdom 1
United States|Canada|France|Japan|Korea, Republic of|Poland|Spain|Taiwan|Turkey 1
United States|Canada|France|Spain|Switzerland|United Kingdom 1
United States|Canada|Korea, Republic of|Spain|Taiwan 1
United States|Czechia|Hungary|Italy|Japan|Korea, Republic of|Mexico|Poland|Romania|Russian Federation|Serbia|Slovakia|Spain|Taiwan|Ukraine 1
United States|France 1
United States|France|Germany|Israel|Netherlands|Spain 1
United States|France|Italy|Japan|Korea, Republic of|Poland|Russian Federation|Spain|Taiwan|Turkey 1
United States|France|Taiwan|United Kingdom 1
United States|Israel 1
United States|Israel|Spain 1
United States|Italy|Taiwan|United Kingdom 1
United States|Japan|Australia|Austria|Belgium|Canada|China|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Korea, Republic of|Poland|Portugal|Russian Federation|Spain|Switzerland|Taiwan|United Kingdom 1
United States|Japan|Korea, Republic of|Spain|Taiwan 1
United States|Korea, Republic of|Ukraine|United Kingdom 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 215
2 37
3 23
4 17
5 21
6 12
7 11
8 9
9 4
10 8
11 6
12 4
13 5
14 2
15 3
16 2
17 4
18 2
19 2
20 5
21 4
23 4
24 1
25 1
26 1
28 2
29 3
30 2
33 2
34 2
35 2
39 1
40 1
42 2
49 1
51 1
53 1
55 1
60 1
64 1
69 1
70 1
71 1
91 1
95 1
105 1
108 1
110 1
114 1
125 1
133 1
149 1
151 1
169 1
189 1
197 1
224 1
228 1
272 1
362 1
508 1

Phase

Phase Study_Count
Phase 2 172
Phase 1 113
Phase 1/Phase 2 63
N/A 45
Phase 3 39
Early Phase 1 8
Phase 2/Phase 3 4
Phase 4 3

Number of Arms

Number_of_Arms Count_of_Studies
1 201
2 161
3 29
4 24
5 9
6 7
7 2
8 2
15 1
NA 11

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 6.000 5.0000 3.00000 1.00000 3.00000 30.0 11.0000 19.00000
1st Qu. 13.500 25.0000 20.00000 30.50000 33.00000 97.5 241.5000 39.50000
Median 15.500 50.0000 35.00000 52.00000 50.50000 253.5 434.0000 60.00000
Mean 23.625 118.0444 59.30089 96.90476 82.15116 265.0 450.0256 93.66667
3rd Qu. 37.500 110.0000 69.00000 137.50000 102.00000 421.0 688.5000 131.00000
Max. 50.000 836.0000 378.00000 412.00000 675.00000 523.0 1113.0000 202.00000

Trial Group Type

group_type Group_Count
Experimental 682
Active Comparator 91
Other 32
Placebo Comparator 22
NA 11
No Intervention 10
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 222
Parallel Assignment 181
Sequential Assignment 35
Factorial Assignment 6
Crossover Assignment 2
NA 1

Primary Purpose

primary_purpose Study_Count
Treatment 394
Diagnostic 21
Supportive Care 15
Other 7
Prevention 4
Health Services Research 3
Basic Science 1
Device Feasibility 1
Screening 1

Observational Studies

Studies by Country

Country Study_Count
United States 9
Canada 3
France 3
Netherlands 3
Belgium 2
NA 2
Taiwan 2
Belgium|Netherlands 1
Brazil 1
Czech Republic 1
Denmark 1
Germany 1
Greece 1
Mexico 1
Singapore 1
United States|Germany|Greece|Italy|Japan|Korea, Republic of|Spain 1

Sites per Study

Site_count Study_Count
1 24
2 3
3 1
4 2
6 1
14 1
18 1

Enrollment Metrics

Measure Observational
Min 17.0000
1st Qu 39.0000
Median 80.0000
Mean 193.5455
3rd Qu 215.0000
Max 1235.0000

Observation Model

observational_model Study_Count
Cohort 23
Case-Only 5
Case-Control 3
Case Control 2

Time Perspective

time_perspective Study_Count
Prospective 26
Retrospective 7

Registries

Studies by Country

Country Study_Count
Denmark 1

Sites per Study

Site_count Study_Count
1 1

Enrollment Metrics

Measure Registries
Min 33
1st Qu 33
Median 33
Mean 33
3rd Qu 33
Max 33

Registry Model

observational_model Study_Count
Other 1

Time Perspective

time_perspective Study_Count
Prospective 1

Follow-up

target_duration Study_Count
1 Day 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04429542 Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT04429542 Recruiting Bicara Therapeutics 2022-12-31
NCT04375384 Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer https://ClinicalTrials.gov/show/NCT04375384 Recruiting Wake Forest University Health Sciences 2022-01-31
NCT04220866 Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) https://ClinicalTrials.gov/show/NCT04220866 Recruiting Merck Sharp & Dohme Corp. 2023-09-28
NCT04128696 Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT04128696 Recruiting GlaxoSmithKline 2023-07-28
NCT04032704 A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT04032704 Recruiting Seattle Genetics, Inc. 2021-07-31
NCT03957096 A Safety Study of SGN-CD47M in Patients With Solid Tumors https://ClinicalTrials.gov/show/NCT03957096 Recruiting Seattle Genetics, Inc. 2022-03-31
NCT03829436 TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers https://ClinicalTrials.gov/show/NCT03829436 Recruiting Tempest Therapeutics 2022-02-18
NCT03485209 Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors https://ClinicalTrials.gov/show/NCT03485209 Recruiting Seattle Genetics, Inc. 2021-06-30
NCT03409458 A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab https://ClinicalTrials.gov/show/NCT03409458 Recruiting Phosplatin Therapeutics 2020-02-01
NCT03389477 Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03389477 Recruiting Washington University School of Medicine 2021-06-30
NCT03383094 Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer https://ClinicalTrials.gov/show/NCT03383094 Recruiting University of California, San Diego 2021-04-30
NCT03381183 IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03381183 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2021-12-31
NCT03370276 Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03370276 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2021-12-31
NCT03823131 Tavo With Electroporation, Pembrolizumab, and Epacadostat in Patients With Unresectable Head and Neck Cancer https://ClinicalTrials.gov/show/NCT03823131 Recruiting University of California, San Francisco 2022-01-01
NCT03356587 A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy https://ClinicalTrials.gov/show/NCT03356587 Recruiting Seoul National University Hospital 2020-01-01
NCT03341936 Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN https://ClinicalTrials.gov/show/NCT03341936 Recruiting Dana-Farber Cancer Institute 2021-06-30
NCT03340896 Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT https://ClinicalTrials.gov/show/NCT03340896 Recruiting Groupe Oncologie Radiotherapie Tete et Cou 2026-09-24
NCT03340038 Use of a Non-ICU Specialty Ward For Immediate Post-operative Management of Head and Neck Free Flaps https://ClinicalTrials.gov/show/NCT03340038 Completed University of California, Davis 2019-02-11
NCT03336606 Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma https://ClinicalTrials.gov/show/NCT03336606 Recruiting Providence Health & Services 2022-07-01
NCT03330249 Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion https://ClinicalTrials.gov/show/NCT03330249 Active, not recruiting Groupe Oncologie Radiotherapie Tete et Cou 2020-07-31
NCT03319459 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03319459 Active, not recruiting Fate Therapeutics 2021-10-31
NCT03313804 Priming Immunotherapy in Advanced Disease With Radiation https://ClinicalTrials.gov/show/NCT03313804 Recruiting University of Kentucky 2020-09-30
NCT03311334 A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03311334 Recruiting Boston Biomedical, Inc 2021-11-30
NCT03291002 Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC https://ClinicalTrials.gov/show/NCT03291002 Recruiting CureVac AG 2022-10-31
NCT03283605 Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas https://ClinicalTrials.gov/show/NCT03283605 Recruiting Centre hospitalier de l’Université de Montréal (CHUM) 2020-03-31
NCT03281499 Transoral Robotic Surgery and Tailored Radiotherapy in Unknown Primary and Small Squamous Cell Head and Neck Cancer https://ClinicalTrials.gov/show/NCT03281499 Active, not recruiting University Health Network, Toronto 2020-08-31
NCT03268993 Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer https://ClinicalTrials.gov/show/NCT03268993 Recruiting University of Pittsburgh 2022-12-31
NCT03260023 Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers Including Oropharyngeal SCCHN https://ClinicalTrials.gov/show/NCT03260023 Recruiting Transgene 2020-12-31
NCT03254927 A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03254927 Recruiting Celldex Therapeutics 2020-07-31
NCT03247712 Neoadjuvant Immunoradiotherapy in Head & Neck Cancer https://ClinicalTrials.gov/show/NCT03247712 Recruiting Providence Health & Services 2025-12-31
NCT03247309 TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) https://ClinicalTrials.gov/show/NCT03247309 Recruiting Immatics US, Inc. 2020-12-31
NCT03238365 Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT03238365 Active, not recruiting Thomas Jefferson University 2019-07-30
NCT03236935 Phase Ib of L-NMMA and Pembrolizumab https://ClinicalTrials.gov/show/NCT03236935 Recruiting The Methodist Hospital System 2020-01-01
NCT03229278 Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma https://ClinicalTrials.gov/show/NCT03229278 Active, not recruiting Rutgers, The State University of New Jersey 2022-07-30
NCT03228667 QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer https://ClinicalTrials.gov/show/NCT03228667 Recruiting Altor BioScience 2021-06-30
NCT03226756 Nivolumab in Recurrent and/or Metastatic SCCHN https://ClinicalTrials.gov/show/NCT03226756 Active, not recruiting UNICANCER 2017-12-31
NCT03212469 A Trial of Durvalumab and Tremelimumab in Comibination With SBRT in Patients With Metastatic Cancer https://ClinicalTrials.gov/show/NCT03212469 Recruiting Gustave Roussy, Cancer Campus, Grand Paris 2019-06-30
NCT03196869 the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer https://ClinicalTrials.gov/show/NCT03196869 Recruiting Guiyang Medical University 2019-04-12
NCT03196843 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. https://ClinicalTrials.gov/show/NCT03196843 Recruiting The First Affiliated Hospital of Dalian Medical University 2020-08-31
NCT03195699 Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers https://ClinicalTrials.gov/show/NCT03195699 Recruiting Tvardi Therapeutics, Incorporated 2020-07-31
NCT03194373 Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03194373 Completed University of Michigan Rogel Cancer Center 2019-02-01
NCT03182959 Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer https://ClinicalTrials.gov/show/NCT03182959 Active, not recruiting University of Arizona 2021-12-31
NCT03134846 Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate https://ClinicalTrials.gov/show/NCT03134846 Recruiting University Medical Center Groningen 2021-01-31
NCT03129061 Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN) https://ClinicalTrials.gov/show/NCT03129061 Active, not recruiting CellSight Technologies, Inc. 2021-04-30
NCT03117257 Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN https://ClinicalTrials.gov/show/NCT03117257 Recruiting Guiyang Medical University 2019-08-19
NCT03109158 NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT03109158 Completed NanoCarrier Co., Ltd. 2019-03-01
NCT03096184 A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers https://ClinicalTrials.gov/show/NCT03096184 Active, not recruiting Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University 2018-07-31
NCT03094169 AVID100 in Advanced Epithelial Carcinomas https://ClinicalTrials.gov/show/NCT03094169 Recruiting Formation Biologics 2020-09-01
NCT03083873 Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck https://ClinicalTrials.gov/show/NCT03083873 Recruiting Iovance Biotherapeutics, Inc. 2021-06-30
NCT03082534 Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03082534 Recruiting University of California, San Diego 2019-12-30
NCT03076281 Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery https://ClinicalTrials.gov/show/NCT03076281 Active, not recruiting Thomas Jefferson University 2018-12-03
NCT03070366 Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC https://ClinicalTrials.gov/show/NCT03070366 Recruiting Groupe Oncologie Radiotherapie Tete et Cou 2020-07-31
NCT03057613 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck https://ClinicalTrials.gov/show/NCT03057613 Recruiting Case Comprehensive Cancer Center 2020-08-15
NCT03053466 APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors https://ClinicalTrials.gov/show/NCT03053466 Active, not recruiting Apollomics (Australia) Pty. Ltd. 2020-02-29
NCT03049618 Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 https://ClinicalTrials.gov/show/NCT03049618 Recruiting University of Southern California 2021-03-10
NCT03040999 Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) https://ClinicalTrials.gov/show/NCT03040999 Active, not recruiting Merck Sharp & Dohme Corp. 2021-04-16
NCT03032250 Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer https://ClinicalTrials.gov/show/NCT03032250 Completed Wake Forest University Health Sciences 2020-04-10
NCT03022409 A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). https://ClinicalTrials.gov/show/NCT03022409 Active, not recruiting AstraZeneca 2020-08-31
NCT02997332 Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT02997332 Recruiting Gustave Roussy, Cancer Campus, Grand Paris 2019-12-31
NCT02955290 CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02955290 Recruiting Roswell Park Cancer Institute 2022-06-09
NCT02952586 Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) https://ClinicalTrials.gov/show/NCT02952586 Active, not recruiting Pfizer 2019-12-23
NCT02949700 Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT02949700 Recruiting Baylor College of Medicine 2020-12-31
NCT02938273 Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) https://ClinicalTrials.gov/show/NCT02938273 Completed The Netherlands Cancer Institute 2019-06-26
NCT02923258 Postoperative CCRT With Docetaxel vs Cisplatin in High Risk HNSCC https://ClinicalTrials.gov/show/NCT02923258 Recruiting Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University 2020-12-31
NCT02915432 The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC https://ClinicalTrials.gov/show/NCT02915432 Active, not recruiting Shanghai Junshi Bioscience Co., Ltd. 2019-09-30
NCT02901483 A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02901483 Recruiting PharmaEngine 2020-12-31
NCT02892201 Pembrolizumab in HNSCC With Residual Disease After Radiation https://ClinicalTrials.gov/show/NCT02892201 Active, not recruiting Yale University 2020-01-31
NCT02882308 Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. https://ClinicalTrials.gov/show/NCT02882308 Completed Hellenic Cooperative Oncology Group 2019-12-31
NCT02862678 Predictive Value of Diffusion-weighted MRI Performed in Early Post-treatment in the Occurrence of Tumor Recurrence or Progression in Head and Neck Squamous Cell Carcinoma Treated With Chemoradiotherapy: a Pilot Study https://ClinicalTrials.gov/show/NCT02862678 Completed CHU de Reims 2019-03-23
NCT02841748 A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study https://ClinicalTrials.gov/show/NCT02841748 Recruiting University of Chicago 2020-12-20
NCT02823574 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT02823574 Active, not recruiting Bristol-Myers Squibb 2019-01-23
NCT02822482 Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss https://ClinicalTrials.gov/show/NCT02822482 Active, not recruiting UNICANCER 2019-11-30
NCT02812524 Ipilimumab for Head and Neck Cancer Patients https://ClinicalTrials.gov/show/NCT02812524 Recruiting Providence Health & Services 2020-11-30
NCT02794675 Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02794675 Completed Case Comprehensive Cancer Center 2019-01-27
NCT02777385 Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02777385 Recruiting University of Pittsburgh 2021-06-30
NCT02776137 Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck https://ClinicalTrials.gov/show/NCT02776137 Active, not recruiting Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University 2017-12-31
NCT02775812 Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT02775812 Active, not recruiting National Cancer Institute (NCI) 2018-12-03
NCT02769520 Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck https://ClinicalTrials.gov/show/NCT02769520 Recruiting University of California, San Diego 2020-06-30
NCT02765503 Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial https://ClinicalTrials.gov/show/NCT02765503 Recruiting International Atomic Energy Agency 2020-11-30
NCT02764593 Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02764593 Active, not recruiting RTOG Foundation, Inc. 2018-09-25
NCT02762513 Expansion Trial for Axitinib In Head And Neck Cancer https://ClinicalTrials.gov/show/NCT02762513 Active, not recruiting University of Michigan Rogel Cancer Center 2020-04-09
NCT02752932 TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility Study https://ClinicalTrials.gov/show/NCT02752932 Completed Lawson Health Research Institute 2017-10-12
NCT02741570 Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT02741570 Active, not recruiting Bristol-Myers Squibb 2021-02-04
NCT02734537 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery https://ClinicalTrials.gov/show/NCT02734537 Recruiting Eastern Cooperative Oncology Group 2022-05-01
NCT02715596 Changes in Body Composition After EPA Supplementation in Head and Neck Patients https://ClinicalTrials.gov/show/NCT02715596 Completed Institut Català d’Oncologia 2019-03-01
NCT02707588 Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC https://ClinicalTrials.gov/show/NCT02707588 Active, not recruiting Groupe Oncologie Radiotherapie Tete et Cou 2020-08-31
NCT02684253 Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) https://ClinicalTrials.gov/show/NCT02684253 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-02-28
NCT02678884 Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study https://ClinicalTrials.gov/show/NCT02678884 Recruiting University Health Network, Toronto 2028-11-30
NCT02643550 Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT02643550 Recruiting Innate Pharma 2021-09-30
NCT02643303 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers https://ClinicalTrials.gov/show/NCT02643303 Recruiting Ludwig Institute for Cancer Research 2022-08-31
NCT02641093 Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT02641093 Recruiting University of Cincinnati 2020-06-30
NCT02639858 Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC https://ClinicalTrials.gov/show/NCT02639858 Recruiting Samyang Biopharmaceuticals Corporation 2020-09-30
NCT02636036 Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors https://ClinicalTrials.gov/show/NCT02636036 Recruiting PsiOxus Therapeutics Ltd 2021-12-31
NCT02626000 Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) https://ClinicalTrials.gov/show/NCT02626000 Active, not recruiting Amgen 2017-11-02
NCT02608736 Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid https://ClinicalTrials.gov/show/NCT02608736 Completed Barretos Cancer Hospital 2016-12-31
NCT02582008 Bupropion Hydrochloride or Patient’s Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy https://ClinicalTrials.gov/show/NCT02582008 Active, not recruiting Wake Forest University Health Sciences 2019-09-28
NCT04139057 EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC https://ClinicalTrials.gov/show/NCT04139057 Recruiting Xinqiao Hospital of Chongqing 2022-02-28
NCT02002182 ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer https://ClinicalTrials.gov/show/NCT02002182 Active, not recruiting Baylor College of Medicine 2022-08-31
NCT02575404 GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients https://ClinicalTrials.gov/show/NCT02575404 Recruiting Providence Health & Services 2020-10-31
NCT02573493 Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) https://ClinicalTrials.gov/show/NCT02573493 Active, not recruiting Washington University School of Medicine 2019-12-12
NCT03153982 Ruxolitinib in Operable Head and Neck Cancer https://ClinicalTrials.gov/show/NCT03153982 Recruiting University of California, San Francisco 2022-06-30
NCT03138889 A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03138889 Recruiting Nektar Therapeutics 2021-06-30
NCT02376699 Safety Study of SEA-CD40 in Cancer Patients https://ClinicalTrials.gov/show/NCT02376699 Recruiting Seattle Genetics, Inc. 2021-10-31
NCT02158234 Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck https://ClinicalTrials.gov/show/NCT02158234 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2021-09-30
NCT02035527 Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT02035527 Completed Ohio State University Comprehensive Cancer Center 2017-04-20
NCT02567422 M6620, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT02567422 Recruiting National Cancer Institute (NCI) 2021-09-12
NCT02565758 ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT02565758 Completed AbbVie 2019-03-25
NCT03396718 De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas https://ClinicalTrials.gov/show/NCT03396718 Recruiting Technische Universität Dresden 2026-01-31
NCT02551159 Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02551159 Active, not recruiting AstraZeneca 2020-06-30
NCT02544880 PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC https://ClinicalTrials.gov/show/NCT02544880 Active, not recruiting University of Miami 2019-06-02
NCT02538510 Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT02538510 Active, not recruiting University of Washington 2019-09-28
NCT02537223 Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02537223 Active, not recruiting University Health Network, Toronto 2018-06-14
NCT02531906 Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation https://ClinicalTrials.gov/show/NCT02531906 Completed Roswell Park Cancer Institute 2018-06-14
NCT02510872 Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection https://ClinicalTrials.gov/show/NCT02510872 Completed University Hospital, Caen 2014-04-30
NCT02510859 Nutrition and Life QUality Patients With Head and Neck Cancers https://ClinicalTrials.gov/show/NCT02510859 Completed University Hospital, Caen 2014-01-31
NCT02508246 WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT02508246 Completed University of Washington 2018-04-26
NCT02507154 Reactivating NK Cells in Treating Refractory Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02507154 Recruiting National University Hospital, Singapore 2019-08-31
NCT02499328 Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck https://ClinicalTrials.gov/show/NCT02499328 Active, not recruiting AstraZeneca 2020-02-28
NCT02499120 Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer https://ClinicalTrials.gov/show/NCT02499120 Active, not recruiting Pfizer 2018-07-19
NCT02495896 Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT02495896 Active, not recruiting University of Southern California 2020-02-28
NCT02473731 A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients https://ClinicalTrials.gov/show/NCT02473731 Completed Celldex Therapeutics 2016-09-22
NCT02454179 Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT02454179 Completed Acerta Pharma BV 2018-05-31
NCT02438995 Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT02438995 Recruiting Northwell Health 2022-07-31
NCT02435602 The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers https://ClinicalTrials.gov/show/NCT02435602 Completed Maria Sklodowska-Curie Institute - Oncology Center 2016-11-30
NCT02432963 Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy https://ClinicalTrials.gov/show/NCT02432963 Active, not recruiting City of Hope Medical Center 2020-02-29
NCT02383966 Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02383966 Active, not recruiting Merck KGaA, Darmstadt, Germany 2018-01-19
NCT02381535 Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin https://ClinicalTrials.gov/show/NCT02381535 Active, not recruiting National Cancer Institute (NCI) 2020-09-30
NCT02369874 Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02369874 Active, not recruiting AstraZeneca 2018-09-10
NCT02369458 Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Platin, 5-FU, Cetuximab, and Taxane https://ClinicalTrials.gov/show/NCT02369458 Recruiting Washington University School of Medicine 2021-06-30
NCT02352792 Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02352792 Recruiting University Hospital Tuebingen 2017-12-31
NCT02350712 Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02350712 Completed Daiichi Sankyo, Inc. 2016-03-31
NCT02347332 Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02347332 Completed Pierre Fabre Medicament 2017-10-20
NCT03386357 Radiotherapy With Pembrolizumab in Metastatic HNSCC https://ClinicalTrials.gov/show/NCT03386357 Recruiting University of Erlangen-Nürnberg Medical School 2021-12-31
NCT02335918 A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT02335918 Completed Celldex Therapeutics 2018-12-12
NCT02325401 Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT02325401 Completed University of Cincinnati 2017-12-26
NCT02319044 Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT02319044 Active, not recruiting AstraZeneca 2016-09-26
NCT02318771 Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer https://ClinicalTrials.gov/show/NCT02318771 Active, not recruiting Thomas Jefferson University 2020-12-31
NCT02296684 Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT02296684 Recruiting Washington University School of Medicine 2021-12-31
NCT02289209 Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck https://ClinicalTrials.gov/show/NCT02289209 Recruiting University of Pittsburgh 2020-12-31
NCT02277197 Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) https://ClinicalTrials.gov/show/NCT02277197 Completed University of Pittsburgh 2016-06-30
NCT02270814 Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT02270814 Active, not recruiting Washington University School of Medicine 2020-11-30
NCT02268695 Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC https://ClinicalTrials.gov/show/NCT02268695 Active, not recruiting Groupe Oncologie Radiotherapie Tete et Cou 2019-01-31
NCT02262741 A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02262741 Completed MedImmune LLC 2017-09-21
NCT02255097 Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) https://ClinicalTrials.gov/show/NCT02255097 Active, not recruiting Merck Sharp & Dohme Corp. 2016-04-22
NCT02254018 Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT02254018 Completed Boehringer Ingelheim 2005-02-28
NCT02216916 Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy https://ClinicalTrials.gov/show/NCT02216916 Recruiting Yonsei University 2019-07-31
NCT02207530 Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT02207530 Active, not recruiting AstraZeneca 2016-09-26
NCT02207439 A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT02207439 Active, not recruiting Abramson Cancer Center of the University of Pennsylvania 2020-12-31
NCT02178072 Window Trial 5-aza in HNSCC, T-tare https://ClinicalTrials.gov/show/NCT02178072 Recruiting Yale University 2020-11-30
NCT02163057 Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT02163057 Completed Inovio Pharmaceuticals 2017-01-23
NCT02145312 An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy. https://ClinicalTrials.gov/show/NCT02145312 Recruiting Yonsei University 2019-05-31
NCT02113878 Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck https://ClinicalTrials.gov/show/NCT02113878 Active, not recruiting Dana-Farber Cancer Institute 2020-12-31
NCT02105636 Trial of Nivolumab vs Therapy of Investigator’s Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) https://ClinicalTrials.gov/show/NCT02105636 Active, not recruiting Bristol-Myers Squibb 2015-11-06
NCT02101034 PD 0332991 and Cetuximab in Patients With Incurable SCCHN https://ClinicalTrials.gov/show/NCT02101034 Active, not recruiting Washington University School of Medicine 2020-09-30
NCT02061631 Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck https://ClinicalTrials.gov/show/NCT02061631 Completed Sanofi 2015-07-31
NCT01307267 A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab https://ClinicalTrials.gov/show/NCT01307267 Completed Pfizer 2019-02-20
NCT01283334 A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer https://ClinicalTrials.gov/show/NCT01283334 Completed Emory University 2013-11-30
NCT01280318 Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery https://ClinicalTrials.gov/show/NCT01280318 Completed Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2011-12-31
NCT02057107 Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN) https://ClinicalTrials.gov/show/NCT02057107 Active, not recruiting University of Pittsburgh 2020-12-31
NCT02047201 Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC https://ClinicalTrials.gov/show/NCT02047201 Completed Lithuanian University of Health Sciences 2016-01-31
NCT02031250 Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer https://ClinicalTrials.gov/show/NCT02031250 Active, not recruiting University of Michigan Rogel Cancer Center 2020-12-31
NCT04196283 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT04196283 Recruiting AbbVie 2022-05-16
NCT03174275 Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03174275 Recruiting UNC Lineberger Comprehensive Cancer Center 2021-09-01
NCT02585973 Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC https://ClinicalTrials.gov/show/NCT02585973 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2020-11-30
NCT02022098 Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial https://ClinicalTrials.gov/show/NCT02022098 Active, not recruiting Debiopharm International SA 2022-04-30
NCT03358472 Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) https://ClinicalTrials.gov/show/NCT03358472 Active, not recruiting Incyte Corporation 2018-07-19
NCT03258554 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin https://ClinicalTrials.gov/show/NCT03258554 Recruiting National Cancer Institute (NCI) 2025-12-31
NCT01612351 Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery https://ClinicalTrials.gov/show/NCT01612351 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2016-11-30
NCT01412229 Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01412229 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2015-06-30
NCT02001623 Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors https://ClinicalTrials.gov/show/NCT02001623 Completed Genmab 2019-05-02
NCT01998542 Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck https://ClinicalTrials.gov/show/NCT01998542 Completed Immunovative Therapies, Ltd. 2017-06-01
NCT01979211 Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01979211 Active, not recruiting University of Cincinnati 2021-01-31
NCT01967927 Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy https://ClinicalTrials.gov/show/NCT01967927 Active, not recruiting University of Arkansas 2020-06-30
NCT01950689 NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) https://ClinicalTrials.gov/show/NCT01950689 Active, not recruiting The Christie NHS Foundation Trust 2020-11-30
NCT01941992 Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients https://ClinicalTrials.gov/show/NCT01941992 Completed Istituto Oncologico Veneto IRCCS 2016-12-31
NCT01931150 Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT https://ClinicalTrials.gov/show/NCT01931150 Completed Memorial Sloan Kettering Cancer Center 2015-09-30
NCT01927744 Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection https://ClinicalTrials.gov/show/NCT01927744 Active, not recruiting M.D. Anderson Cancer Center 2020-12-31
NCT01911598 A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) https://ClinicalTrials.gov/show/NCT01911598 Completed Genentech, Inc. 2017-06-22
NCT01864850 Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC https://ClinicalTrials.gov/show/NCT01864850 Active, not recruiting Groupe Oncologie Radiotherapie Tete et Cou 2020-05-31
NCT01846091 Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer https://ClinicalTrials.gov/show/NCT01846091 Active, not recruiting Mayo Clinic 2019-09-18
NCT01836029 Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01836029 Completed Celgene 2016-04-13
NCT01824823 Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence https://ClinicalTrials.gov/show/NCT01824823 Active, not recruiting Eastern Cooperative Oncology Group 2015-12-13
NCT01807546 Oral Rigosertib for Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT01807546 Completed Onconova Therapeutics, Inc. 2015-03-31
NCT01794481 Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy https://ClinicalTrials.gov/show/NCT01794481 Completed University of Michigan Rogel Cancer Center 2014-08-31
NCT01783587 Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer https://ClinicalTrials.gov/show/NCT01783587 Active, not recruiting Dana-Farber Cancer Institute 2020-06-30
NCT01774760 Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer https://ClinicalTrials.gov/show/NCT01774760 Completed Turku University Hospital 2016-09-30
NCT01758731 Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History https://ClinicalTrials.gov/show/NCT01758731 Completed University of Colorado, Denver 2016-12-05
NCT01737008 Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01737008 Completed University Health Network, Toronto 2015-02-28
NCT01727076 Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer https://ClinicalTrials.gov/show/NCT01727076 Completed National Cancer Institute (NCI) 2016-06-30
NCT01716416 Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) https://ClinicalTrials.gov/show/NCT01716416 Completed Washington University School of Medicine 2015-07-31
NCT01711541 Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer https://ClinicalTrials.gov/show/NCT01711541 Active, not recruiting National Cancer Institute (NCI) 2018-02-15
NCT01697800 A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract https://ClinicalTrials.gov/show/NCT01697800 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2014-07-14
NCT01696955 Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT01696955 Completed National Cancer Institute (NCI) 2017-05-05
NCT01695122 Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT01695122 Completed Instituto do Cancer do Estado de São Paulo 2014-11-30
NCT03349710 Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer https://ClinicalTrials.gov/show/NCT03349710 Completed Bristol-Myers Squibb 2019-10-14
NCT01598077 A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer https://ClinicalTrials.gov/show/NCT01598077 Completed Novartis 2014-03-31
NCT01592721 Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT01592721 Active, not recruiting The University of Texas Health Science Center at San Antonio 2024-01-31
NCT01588431 Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer https://ClinicalTrials.gov/show/NCT01588431 Active, not recruiting The University of Texas Health Science Center at San Antonio 2021-12-31
NCT01581970 Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer https://ClinicalTrials.gov/show/NCT01581970 Completed Masonic Cancer Center, University of Minnesota 2015-09-30
NCT01577173 A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck https://ClinicalTrials.gov/show/NCT01577173 Completed Genentech, Inc. 2015-06-30
NCT01538381 Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01538381 Completed European Organisation for Research and Treatment of Cancer - EORTC 2015-08-31
NCT01528163 Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01528163 Completed Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2014-11-30
NCT01515137 Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT01515137 Completed University of Pittsburgh 2014-09-30
NCT01484847 A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT01484847 Completed University Health Network, Toronto 2013-03-31
NCT01469546 Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer https://ClinicalTrials.gov/show/NCT01469546 Completed University of Michigan Rogel Cancer Center 2015-04-30
NCT01468896 Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT01468896 Active, not recruiting National Cancer Institute (NCI) 2015-09-29
NCT01458392 Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01458392 Completed Acceleron Pharma, Inc. 2015-06-30
NCT01449201 PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT01449201 Completed Yonsei University 2013-10-31
NCT01427478 Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01427478 Active, not recruiting Centre Leon Berard 2021-11-30
NCT01425736 Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT01425736 Completed Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University 2011-01-31
NCT01417936 Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy https://ClinicalTrials.gov/show/NCT01417936 Completed Symphogen A/S 2012-10-31
NCT01415674 Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients https://ClinicalTrials.gov/show/NCT01415674 Completed UNICANCER 2015-07-31
NCT01386632 Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma https://ClinicalTrials.gov/show/NCT01386632 Active, not recruiting Sanford Health 2014-08-31
NCT01379339 Cabazitaxel - PF Induction Chemotherapy https://ClinicalTrials.gov/show/NCT01379339 Completed Icahn School of Medicine at Mount Sinai 2015-01-31
NCT01353625 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. https://ClinicalTrials.gov/show/NCT01353625 Active, not recruiting Celgene 2020-12-28
NCT01344356 Stereotactic Body Radiotherapy for Head and Neck Tumors https://ClinicalTrials.gov/show/NCT01344356 Completed Mercy Research 2018-05-31
NCT01332266 E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01332266 Completed Eisai Inc. 2016-01-31
NCT04413214 Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial https://ClinicalTrials.gov/show/NCT04413214 Recruiting Shanghai Jiao Tong University School of Medicine 2020-12-31
NCT04399785 Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC https://ClinicalTrials.gov/show/NCT04399785 Recruiting West China Hospital 2021-12-01
NCT04397341 Biweekly TPF Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of Head and Neck https://ClinicalTrials.gov/show/NCT04397341 Completed China Medical University Hospital 2016-08-30
NCT04361409 Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT04361409 Completed China Medical University Hospital 2016-11-30
NCT04348916 Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors https://ClinicalTrials.gov/show/NCT04348916 Recruiting Oncorus, Inc. 2023-06-30
NCT04344795 Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors https://ClinicalTrials.gov/show/NCT04344795 Recruiting Tempest Therapeutics 2021-08-31
NCT04326257 Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy https://ClinicalTrials.gov/show/NCT04326257 Recruiting University of Pittsburgh 2022-03-01
NCT04284540 Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT04284540 Recruiting Icahn School of Medicine at Mount Sinai 2024-05-31
NCT04282109 Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) https://ClinicalTrials.gov/show/NCT04282109 Recruiting Grupo Español de Tratamiento de Tumores de Cabeza y Cuello 2023-08-31
NCT04278092 Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure https://ClinicalTrials.gov/show/NCT04278092 Recruiting Medical University of Vienna 2021-12-31
NCT04266470 Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region https://ClinicalTrials.gov/show/NCT04266470 Recruiting Wake Forest University Health Sciences 2020-12-31
NCT04253808 Feasibility of a Carbohydrate-restricted, High-fat Diet on Head and Neck Squamous Cell Carcinoma Outcomes https://ClinicalTrials.gov/show/NCT04253808 Recruiting University of Illinois at Urbana-Champaign 2022-12-31
NCT04247282 Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection https://ClinicalTrials.gov/show/NCT04247282 Recruiting National Institutes of Health Clinical Center (CC) 2022-08-31
NCT04242173 Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC https://ClinicalTrials.gov/show/NCT04242173 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2022-01-31
NCT04234113 Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT04234113 Recruiting Sotio a.s. 2022-03-31
NCT04222543 Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging https://ClinicalTrials.gov/show/NCT04222543 Recruiting Radboud University 2022-09-01
NCT04220775 Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer https://ClinicalTrials.gov/show/NCT04220775 Recruiting M.D. Anderson Cancer Center 2021-08-31
NCT04213404 Ribociclib and Spartalizumab in R/M HNSCC https://ClinicalTrials.gov/show/NCT04213404 Recruiting National Taiwan University Hospital 2024-01-31
NCT04193293 A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer https://ClinicalTrials.gov/show/NCT04193293 Recruiting Verastem, Inc. 2021-11-30
NCT04183166 A Clinical Trial Evaluating TG4050 in Head and Neck Cancer https://ClinicalTrials.gov/show/NCT04183166 Recruiting Transgene 2021-11-30
NCT04164238 Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients https://ClinicalTrials.gov/show/NCT04164238 Recruiting First Affiliated Hospital of Zhejiang University 2020-11-07
NCT04152018 Study of PF‑06940434 in Patients With Advanced or Metastatic Solid Tumors. https://ClinicalTrials.gov/show/NCT04152018 Recruiting Pfizer 2024-03-02
NCT04146402 SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT04146402 Recruiting Sinocelltech Ltd. 2022-01-29
NCT04144517 A Study of ALKS 4230 With Pembrolizumab in Head and Neck Cancer https://ClinicalTrials.gov/show/NCT04144517 Recruiting Alkermes, Inc. 2021-09-30
NCT04117139 The Diagnostic Value of PET/MRI in Head and Neck Cancer https://ClinicalTrials.gov/show/NCT04117139 Recruiting Odense University Hospital 2021-09-30
NCT04110249 Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer https://ClinicalTrials.gov/show/NCT04110249 Recruiting Roswell Park Cancer Institute 2020-07-13
NCT04098458 Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC https://ClinicalTrials.gov/show/NCT04098458 Completed Medical University of South Carolina 2020-04-14
NCT04096638 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT04096638 Recruiting Spring Bank Pharmaceuticals, Inc. 2021-12-31
NCT04091867 sEphB4-HSA With Cetuximab and RT in Patients With High Risk, LAHNSCC and Heavy Smoking Histories https://ClinicalTrials.gov/show/NCT04091867 Recruiting University of Colorado, Denver 2021-09-30
NCT04080804 Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer https://ClinicalTrials.gov/show/NCT04080804 Recruiting University of Pittsburgh 2021-07-31
NCT04052204 Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT04052204 Recruiting Pfizer 2022-10-09
NCT04045496 A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT04045496 Recruiting Jacobio Pharmaceuticals Co., Ltd. 2021-03-31
NCT04042935 Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC https://ClinicalTrials.gov/show/NCT04042935 Recruiting University of Colorado, Denver 2020-12-07
NCT04034225 Addition of SNS-301 to Ongoing Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN https://ClinicalTrials.gov/show/NCT04034225 Recruiting Sensei Biotherapeutics, Inc. 2021-02-01
NCT04030130 Navigation vs Usual Care for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC https://ClinicalTrials.gov/show/NCT04030130 Recruiting Medical University of South Carolina 2024-08-31
NCT04007744 Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT04007744 Recruiting Mayo Clinic 2021-07-31
NCT04001543 Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer https://ClinicalTrials.gov/show/NCT04001543 Recruiting Institut du Cancer de Montpellier - Val d’Aurelle 2025-05-31
NCT04000529 Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies https://ClinicalTrials.gov/show/NCT04000529 Recruiting Novartis 2022-03-22
NCT03993353 Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer https://ClinicalTrials.gov/show/NCT03993353 Recruiting University of California, San Diego 2022-12-31
NCT03978689 A Phase 1 Study in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03978689 Recruiting Cue Biopharma 2021-06-30
NCT03953976 INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy https://ClinicalTrials.gov/show/NCT03953976 Recruiting University of Texas Southwestern Medical Center 2022-07-31
NCT03944915 De-Escalation Therapy for Human Papillomavirus Negative Disease https://ClinicalTrials.gov/show/NCT03944915 Recruiting University of Chicago 2022-07-01
NCT03942380 Cell-free Tumor DNA in Head and Neck Cancer Patients https://ClinicalTrials.gov/show/NCT03942380 Recruiting Rigshospitalet, Denmark 2025-02-01
NCT03917381 GEN1046 Safety Trial in Patients With Malignant Solid Tumors https://ClinicalTrials.gov/show/NCT03917381 Recruiting Genmab 2021-10-31
NCT03916627 Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC https://ClinicalTrials.gov/show/NCT03916627 Recruiting Regeneron Pharmaceuticals 2022-06-20
NCT03896412 Detection of Circulating Tumor DNA in p16- Locally Advanced Head Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03896412 Recruiting Centre Henri Becquerel 2021-05-19
NCT03894618 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT03894618 Recruiting Shattuck Labs, Inc. 2022-02-02
NCT03880396 Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN https://ClinicalTrials.gov/show/NCT03880396 Active, not recruiting Assiut University 2019-12-10
NCT03878979 Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN https://ClinicalTrials.gov/show/NCT03878979 Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2021-07-31
NCT03874741 SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03874741 Active, not recruiting Sinocelltech Ltd. 2020-06-30
NCT03868020 Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease https://ClinicalTrials.gov/show/NCT03868020 Recruiting M.D. Anderson Cancer Center 2021-08-31
NCT03855384 Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck(R/M SCCHN) https://ClinicalTrials.gov/show/NCT03855384 Recruiting Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2020-12-31
NCT03849469 A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03849469 Recruiting Xencor, Inc. 2026-09-30
NCT03838601 Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 https://ClinicalTrials.gov/show/NCT03838601 Recruiting University Health Network, Toronto 2020-11-02
NCT03830385 Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck https://ClinicalTrials.gov/show/NCT03830385 Recruiting Sun Yat-sen University 2021-02-15
NCT03829501 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer https://ClinicalTrials.gov/show/NCT03829501 Recruiting Kymab Limited 2023-05-31
NCT03818542 A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03818542 Recruiting AbbVie 2021-03-01
NCT03818061 Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT03818061 Recruiting Centre Leon Berard 2022-03-01
NCT03817307 Validation of USPIO-enhanced MRI for Detection of Lymph Node Metastases in Head and Neck Carcinoma https://ClinicalTrials.gov/show/NCT03817307 Recruiting Radboud University 2020-09-30
NCT03815903 Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03815903 Recruiting Barretos Cancer Hospital 2020-12-31
NCT03813836 Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC https://ClinicalTrials.gov/show/NCT03813836 Recruiting University College, London 2021-12-31
NCT03811652 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03811652 Completed MedImmune LLC 2019-12-10
NCT03809624 Study of INBRX-105 in Patients With Solid Tumors https://ClinicalTrials.gov/show/NCT03809624 Recruiting Inhibrx, Inc. 2021-07-31
NCT03803774 Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03803774 Recruiting National Cancer Institute (NCI) 2020-07-31
NCT03799744 Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03799744 Recruiting Institut Català d’Oncologia 2021-09-30
NCT03795610 Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03795610 Recruiting University of California, San Diego 2022-06-30
NCT03789097 Vaccination With Flt3L, Radiation, and Poly-ICLC https://ClinicalTrials.gov/show/NCT03789097 Recruiting Icahn School of Medicine at Mount Sinai 2023-06-30
NCT03788785 Smoking Tobacco Cessation Integrated Program of Patients Treated for the Head and the Neck Cancer https://ClinicalTrials.gov/show/NCT03788785 Recruiting Assistance Publique - Hôpitaux de Paris 2022-06-30
NCT03775525 Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT03775525 Recruiting Genzada Pharmaceuticals USA, Inc. 2020-09-30
NCT03768856 Temporally Feathered Radiation Therapy (TFRT) for Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03768856 Completed Case Comprehensive Cancer Center 2019-07-18
NCT03765918 Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) https://ClinicalTrials.gov/show/NCT03765918 Recruiting Merck Sharp & Dohme Corp. 2025-07-30
NCT03758781 IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03758781 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2021-02-28
NCT03752398 A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) https://ClinicalTrials.gov/show/NCT03752398 Recruiting Xencor, Inc. 2024-09-30
NCT03740100 Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations https://ClinicalTrials.gov/show/NCT03740100 Recruiting PIQUR Therapeutics AG 2020-12-31
NCT03739931 Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies https://ClinicalTrials.gov/show/NCT03739931 Recruiting ModernaTX, Inc. 2020-06-30
NCT03735680 A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer https://ClinicalTrials.gov/show/NCT03735680 Recruiting OncoNano Medicine, Inc. 2020-09-30
NCT03735628 An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03735628 Recruiting Bayer 2022-12-30
NCT03735290 A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer https://ClinicalTrials.gov/show/NCT03735290 Recruiting Immunicum AB 2022-12-31
NCT03733210 Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer https://ClinicalTrials.gov/show/NCT03733210 Recruiting Stanford University 2021-02-07
NCT03723967 FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel https://ClinicalTrials.gov/show/NCT03723967 Recruiting Centre Leon Berard 2022-03-15
NCT03720158 Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of Head and Neck Cancer Patients https://ClinicalTrials.gov/show/NCT03720158 Recruiting Coordinación de Investigación en Salud, Mexico 2021-12-31
NCT03719690 Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy https://ClinicalTrials.gov/show/NCT03719690 Recruiting Kura Oncology, Inc. 2021-05-31
NCT03715946 Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer https://ClinicalTrials.gov/show/NCT03715946 Recruiting University of Pittsburgh 2021-05-31
NCT03713372 Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03713372 Active, not recruiting Sinocelltech Ltd. 2020-02-11
NCT03695510 Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study) https://ClinicalTrials.gov/show/NCT03695510 Recruiting National Taiwan University Hospital 2021-04-30
NCT03691714 Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03691714 Recruiting University of Cincinnati 2021-10-31
NCT03690986 VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer https://ClinicalTrials.gov/show/NCT03690986 Recruiting Emory University 2020-11-30
NCT03689192 Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03689192 Recruiting Herlev Hospital 2020-12-31
NCT03684785 Intratumoral AST-008 Combined With Pembrolizumab or Cemiplimab in Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03684785 Recruiting Exicure, Inc. 2021-06-30
NCT03665285 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03665285 Recruiting NextCure, Inc. 2021-05-01
NCT03655444 Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy https://ClinicalTrials.gov/show/NCT03655444 Recruiting Washington University School of Medicine 2022-06-30
NCT03652077 A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies https://ClinicalTrials.gov/show/NCT03652077 Recruiting Incyte Corporation 2021-01-31
NCT03650764 Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03650764 Recruiting Washington University School of Medicine 2021-11-30
NCT03649048 Low-Dose Weekly vs High-Dose Cisplatin https://ClinicalTrials.gov/show/NCT03649048 Recruiting Lawson Health Research Institute 2021-02-28
NCT03647163 Combination Therapy With Intravenous VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and HNSCC https://ClinicalTrials.gov/show/NCT03647163 Recruiting Vyriad, Inc. 2020-11-01
NCT03646461 Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC https://ClinicalTrials.gov/show/NCT03646461 Recruiting University of California, San Diego 2021-05-30
NCT03645928 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors https://ClinicalTrials.gov/show/NCT03645928 Recruiting Iovance Biotherapeutics, Inc. 2023-12-31
NCT03635164 Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03635164 Recruiting University of Colorado, Denver 2020-06-25
NCT03633110 Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine https://ClinicalTrials.gov/show/NCT03633110 Active, not recruiting Genocea Biosciences, Inc. 2022-12-31
NCT03629756 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies https://ClinicalTrials.gov/show/NCT03629756 Recruiting Arcus Biosciences, Inc. 2021-01-31
NCT03624231 Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC https://ClinicalTrials.gov/show/NCT03624231 Recruiting Charite University, Berlin, Germany 2021-08-31
NCT03620123 A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT03620123 Recruiting AIO-Studien-gGmbH 2022-07-31
NCT03618654 Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03618654 Recruiting Thomas Jefferson University 2020-07-31
NCT03602911 A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients https://ClinicalTrials.gov/show/NCT03602911 Recruiting West Virginia University 2019-07-30
NCT03590054 A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies https://ClinicalTrials.gov/show/NCT03590054 Recruiting University of California, San Francisco 2022-02-15
NCT03589339 NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy https://ClinicalTrials.gov/show/NCT03589339 Recruiting Nanobiotix 2023-03-30
NCT03578406 HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer https://ClinicalTrials.gov/show/NCT03578406 Recruiting Xinqiao Hospital of Chongqing 2020-08-30
NCT03576417 A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck https://ClinicalTrials.gov/show/NCT03576417 Recruiting Groupe Oncologie Radiotherapie Tete et Cou 2021-12-31
NCT03575949 Dual-time Point (DTP) FDG PET CT for the Post-treatment Assessment of Head and Neck Tumors Following Definitive Chemoradiation Therapy https://ClinicalTrials.gov/show/NCT03575949 Recruiting M.D. Anderson Cancer Center 2022-12-31
NCT03575598 Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study https://ClinicalTrials.gov/show/NCT03575598 Recruiting University Health Network, Toronto 2020-08-30
NCT03574792 Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy https://ClinicalTrials.gov/show/NCT03574792 Recruiting Roswell Park Cancer Institute 2020-09-03
NCT03565783 Cemiplimab in Treating Participants With Recurrent Stage III-IV Head and Neck Squamous Cell Cancer Before Surgery https://ClinicalTrials.gov/show/NCT03565783 Recruiting M.D. Anderson Cancer Center 2021-07-31
NCT03556228 Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT03556228 Recruiting VM Oncology, LLC 2021-06-30
NCT03552965 Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC https://ClinicalTrials.gov/show/NCT03552965 Enrolling by invitation University of Arkansas 2020-07-01
NCT03552718 QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. https://ClinicalTrials.gov/show/NCT03552718 Recruiting NantBioScience, Inc. 2019-12-30
NCT03546582 SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma https://ClinicalTrials.gov/show/NCT03546582 Recruiting RTOG Foundation, Inc. 2024-07-31
NCT03540563 ctDNA as a Biomarker for Treatment Response in HNSCC https://ClinicalTrials.gov/show/NCT03540563 Recruiting The Netherlands Cancer Institute 2021-05-31
NCT03538028 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies https://ClinicalTrials.gov/show/NCT03538028 Recruiting Incyte Corporation 2020-09-24
NCT03525392 Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. https://ClinicalTrials.gov/show/NCT03525392 Recruiting Ipsen 2021-04-20
NCT03524326 Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03524326 Recruiting Memorial Sloan Kettering Cancer Center 2021-04-30
NCT03522584 Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03522584 Recruiting University of Washington 2021-02-15
NCT03521570 Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer https://ClinicalTrials.gov/show/NCT03521570 Recruiting Emory University 2020-12-31
NCT03519048 Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03519048 Recruiting Gustave Roussy, Cancer Campus, Grand Paris 2026-01-31
NCT03518671 Building a Renewed ImaGe After Head & Neck Cancer Treatment https://ClinicalTrials.gov/show/NCT03518671 Completed Medical University of South Carolina 2019-08-22
NCT03517488 A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03517488 Recruiting Xencor, Inc. 2020-12-31
NCT03510390 Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation https://ClinicalTrials.gov/show/NCT03510390 Recruiting University Hospital Inselspital, Berne 2020-09-15
NCT03509012 Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03509012 Active, not recruiting AstraZeneca 2022-04-04
NCT03498378 Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03498378 Recruiting University of California, San Diego 2021-08-31
NCT03491176 Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer https://ClinicalTrials.gov/show/NCT03491176 Recruiting M.D. Anderson Cancer Center 2020-05-31
NCT03480672 Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03480672 Recruiting University of Leipzig 2022-08-31
NCT03474497 UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade https://ClinicalTrials.gov/show/NCT03474497 Recruiting University of California, Davis 2021-07-01
NCT03468218 Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer https://ClinicalTrials.gov/show/NCT03468218 Recruiting Emory University 2020-11-30
NCT03454451 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers https://ClinicalTrials.gov/show/NCT03454451 Recruiting Corvus Pharmaceuticals, Inc. 2022-03-31
NCT03452137 A Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT03452137 Recruiting Hoffmann-La Roche 2021-03-22
NCT03435640 A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies https://ClinicalTrials.gov/show/NCT03435640 Recruiting Nektar Therapeutics 2021-09-30
NCT03433027 A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03433027 Completed Benitec BioPharma Ltd 2018-12-12
NCT03426657 Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC https://ClinicalTrials.gov/show/NCT03426657 Recruiting University of Erlangen-Nürnberg Medical School 2021-04-30
NCT03422536 Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03422536 Recruiting University of Arizona 2020-12-31
NCT03421912 Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR) https://ClinicalTrials.gov/show/NCT03421912 Recruiting Centre Leon Berard 2019-05-31
NCT03412058 Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists https://ClinicalTrials.gov/show/NCT03412058 Recruiting UNICANCER 2020-05-31
NCT01252628 Phase 1 and 2 Study of PX-866 and Cetuximab https://ClinicalTrials.gov/show/NCT01252628 Completed Seattle Genetics, Inc. 2013-11-30
NCT01218048 ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT01218048 Completed University of Pittsburgh 2015-11-04
NCT01204099 Study of PX-866 and Docetaxel in Solid Tumors https://ClinicalTrials.gov/show/NCT01204099 Completed Seattle Genetics, Inc. 2013-12-31
NCT01195922 Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT01195922 Completed National Institutes of Health Clinical Center (CC) 2015-06-30
NCT01177956 A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck https://ClinicalTrials.gov/show/NCT01177956 Completed Merck KGaA, Darmstadt, Germany 2011-01-31
NCT01172769 Efficacy Study of Temsirolimus to Treat Head and Neck Cancer https://ClinicalTrials.gov/show/NCT01172769 Completed Hannover Medical School 2012-03-31
NCT01154920 Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT01154920 Active, not recruiting M.D. Anderson Cancer Center 2020-07-31
NCT01115790 A Phase 1 Study in Participants With Advanced Cancer https://ClinicalTrials.gov/show/NCT01115790 Completed Eli Lilly and Company 2016-01-31
NCT01104922 Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01104922 Active, not recruiting University of Pittsburgh 2020-07-31
NCT01086826 Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01086826 Completed Associazione Volontari Pazienti Oncologici 2014-04-30
NCT01064479 Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01064479 Active, not recruiting M.D. Anderson Cancer Center 2021-02-28
NCT01059643 A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01059643 Completed Eli Lilly and Company 2012-12-31
NCT01054625 Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) https://ClinicalTrials.gov/show/NCT01054625 Completed Genmab 2011-07-31
NCT01046266 A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT01046266 Completed Hoffmann-La Roche 2012-06-30
NCT01045421 Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies https://ClinicalTrials.gov/show/NCT01045421 Completed Millennium Pharmaceuticals, Inc. 2013-05-31
NCT01040832 EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT01040832 Completed EMD Serono 2012-01-31
NCT01012258 Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects https://ClinicalTrials.gov/show/NCT01012258 Completed Merck KGaA, Darmstadt, Germany 2010-09-30
NCT00999700 Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin https://ClinicalTrials.gov/show/NCT00999700 Active, not recruiting Gruppo Oncologico del Nord-Ovest 2016-12-31
NCT00995293 Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial https://ClinicalTrials.gov/show/NCT00995293 Completed Sanofi 2018-01-26
NCT00971932 Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) https://ClinicalTrials.gov/show/NCT00971932 Completed Merck KGaA, Darmstadt, Germany 2011-03-31
NCT00968435 Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT00968435 Completed Memorial Sloan Kettering Cancer Center 2016-08-31
NCT00957853 Preoperative Treatment With Cetuximab and/or IMC-A12 https://ClinicalTrials.gov/show/NCT00957853 Completed M.D. Anderson Cancer Center 2018-08-15
NCT00957086 Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer https://ClinicalTrials.gov/show/NCT00957086 Recruiting National Cancer Centre, Singapore 2020-06-30
NCT00899054 Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer https://ClinicalTrials.gov/show/NCT00899054 Completed Piramal Enterprises Limited 2011-01-31
NCT00894413 A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract https://ClinicalTrials.gov/show/NCT00894413 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2012-03-31
NCT00865098 Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) https://ClinicalTrials.gov/show/NCT00865098 Completed Merck KGaA, Darmstadt, Germany 2010-06-30
NCT03405142 Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer https://ClinicalTrials.gov/show/NCT03405142 Recruiting Stanford University 2021-02-01
NCT03139058 Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT03139058 Recruiting Centre Hospitalier Universitaire, Amiens 2019-06-20
NCT00824343 A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer https://ClinicalTrials.gov/show/NCT00824343 Completed Piramal Enterprises Limited 2011-04-30
NCT04146181 Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT04146181 Recruiting Sinocelltech Ltd. 2021-06-30
NCT03245736 Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. https://ClinicalTrials.gov/show/NCT03245736 Completed Genmab 2019-01-10
NCT04445064 Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. https://ClinicalTrials.gov/show/NCT04445064 Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2024-06-08
NCT03625323 Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC https://ClinicalTrials.gov/show/NCT03625323 Recruiting Immutep S.A. 2020-12-31
NCT02524275 Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT02524275 Recruiting University of Nebraska 2021-06-01
NCT03245489 Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT03245489 Recruiting Medical University of South Carolina 2020-12-30
NCT03317327 REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors https://ClinicalTrials.gov/show/NCT03317327 Recruiting Oslo University Hospital 2023-11-02
NCT03088059 Biomarker-based Study in R/M SCCHN https://ClinicalTrials.gov/show/NCT03088059 Recruiting European Organisation for Research and Treatment of Cancer - EORTC 2021-06-30
NCT02999646 Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC https://ClinicalTrials.gov/show/NCT02999646 Recruiting Swiss Group for Clinical Cancer Research 2022-12-31
NCT02658214 Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT02658214 Completed AstraZeneca 2019-11-14
NCT04199104 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010) https://ClinicalTrials.gov/show/NCT04199104 Recruiting Merck Sharp & Dohme Corp. 2023-11-13
NCT02124707 Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN https://ClinicalTrials.gov/show/NCT02124707 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2020-02-27
NCT02054442 A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck https://ClinicalTrials.gov/show/NCT02054442 Active, not recruiting Radboud University 2019-12-31
NCT04440917 Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT04440917 Recruiting Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University 2022-06-30
NCT03998696 An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer. https://ClinicalTrials.gov/show/NCT03998696 Completed Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 2018-06-30
NCT00771641 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00771641 Completed Radiation Therapy Oncology Group 2002-08-31
NCT00756444 A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00756444 Completed Amgen 2012-03-30
NCT00736944 Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer https://ClinicalTrials.gov/show/NCT00736944 Active, not recruiting Washington University School of Medicine 2010-08-31
NCT00736619 Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) https://ClinicalTrials.gov/show/NCT00736619 Completed Memorial Sloan Kettering Cancer Center 2016-08-31
NCT00671437 Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer https://ClinicalTrials.gov/show/NCT00671437 Completed Washington University School of Medicine 2011-12-31
NCT00625456 Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT00625456 Completed SillaJen, Inc. 2010-04-30
NCT00623558 Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) https://ClinicalTrials.gov/show/NCT00623558 Completed Seoul National University Hospital 2012-11-30
NCT00611754 Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00611754 Completed Sanofi NA
NCT00609284 Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux https://ClinicalTrials.gov/show/NCT00609284 Completed Groupe Oncologie Radiotherapie Tete et Cou 2018-03-26
NCT00596219 Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT00596219 Completed Memorial Sloan Kettering Cancer Center 2006-10-31
NCT00547157 Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00547157 Completed Amgen 2011-12-31
NCT00519077 Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00519077 Completed University of Chicago 2008-05-31
NCT00513383 Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck https://ClinicalTrials.gov/show/NCT00513383 Completed Massachusetts General Hospital 2010-10-31
NCT00496652 DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC https://ClinicalTrials.gov/show/NCT00496652 Completed Danish Head and Neck Cancer Group 2012-07-31
NCT00494182 Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer https://ClinicalTrials.gov/show/NCT00494182 Active, not recruiting M.D. Anderson Cancer Center 2020-05-31
NCT00474825 Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00474825 Completed National Baromedical Services 2011-02-28
NCT00459043 Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck https://ClinicalTrials.gov/show/NCT00459043 Completed Dana-Farber Cancer Institute 2010-03-31
NCT00454779 PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response https://ClinicalTrials.gov/show/NCT00454779 Completed Amgen 2012-06-11
NCT00446446 PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) https://ClinicalTrials.gov/show/NCT00446446 Completed Amgen 2010-12-15
NCT00442455 Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00442455 Completed Grupo de Investigación Clínica en Oncología Radioterapia 2015-08-31
NCT00402545 C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00402545 Completed Dana-Farber Cancer Institute 2009-07-31
NCT00371566 A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer https://ClinicalTrials.gov/show/NCT00371566 Completed GlaxoSmithKline 2007-12-31
NCT00358930 A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00358930 Completed ArQule 2007-08-31
NCT00357149 Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS) https://ClinicalTrials.gov/show/NCT00357149 Completed Sanofi 2008-02-29
NCT00343083 Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442) https://ClinicalTrials.gov/show/NCT00343083 Completed University of Maryland, Baltimore 2011-06-30
NCT00318890 Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00318890 Completed University of Alabama at Birmingham 2007-04-30
NCT00304278 Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA) https://ClinicalTrials.gov/show/NCT00304278 Completed Southern Illinois University 2015-05-31
NCT00268671 Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN) https://ClinicalTrials.gov/show/NCT00268671 Completed Sanofi 2006-04-30
NCT00258310 Ph II Study Examining Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation &/or Chemotherapy https://ClinicalTrials.gov/show/NCT00258310 Completed Barbara Ann Karmanos Cancer Institute 2011-02-28
NCT00257738 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00257738 Completed University of Maryland, Baltimore 2012-10-31
NCT00229723 IRESSAâ„¢ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT00229723 Completed AstraZeneca NA
NCT00210470 A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer https://ClinicalTrials.gov/show/NCT00210470 Completed Brooklyn ImmunoTherapeutics, LLC 2010-12-31
NCT00206752 Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck https://ClinicalTrials.gov/show/NCT00206752 Completed Beth Israel Medical Center 2015-02-28
NCT00174837 TRACE: Tirapazamine-Radiation And Cisplatin Evaluation https://ClinicalTrials.gov/show/NCT00174837 Completed Sanofi 2008-01-31
NCT00162708 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC https://ClinicalTrials.gov/show/NCT00162708 Completed Gustave Roussy, Cancer Campus, Grand Paris NA
NCT00139269 Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00139269 Completed Dana-Farber Cancer Institute 2006-12-31
NCT00139243 Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00139243 Completed Dana-Farber Cancer Institute 2006-01-31
NCT00122460 Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) https://ClinicalTrials.gov/show/NCT00122460 Completed Merck KGaA, Darmstadt, Germany 2007-03-31
NCT00084682 Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00084682 Completed National Cancer Institute (NCI) 2008-11-30
NCT00103259 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00103259 Completed National Cancer Institute (NCI) 2011-11-30
NCT00096174 Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00096174 Completed Eastern Cooperative Oncology Group 2009-07-31
NCT00093041 Zalutumumab in Head and Neck Cancer https://ClinicalTrials.gov/show/NCT00093041 Completed Genmab 2005-01-31
NCT00083057 Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00083057 Completed National Institutes of Health Clinical Center (CC) 2010-10-31
NCT00079053 Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck https://ClinicalTrials.gov/show/NCT00079053 Completed Canadian Cancer Trials Group 2008-12-09
NCT00158652 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC https://ClinicalTrials.gov/show/NCT00158652 Completed Groupe Oncologie Radiotherapie Tete et Cou 2011-03-31
NCT00206219 Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) https://ClinicalTrials.gov/show/NCT00206219 Completed AstraZeneca 2007-09-30

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03225157 Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation https://ClinicalTrials.gov/show/NCT03225157 Completed National Institutes of Health Clinical Center (CC) 2020-02-28
NCT03161613 Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico https://ClinicalTrials.gov/show/NCT03161613 Recruiting Bristol-Myers Squibb 2019-04-01
NCT03114163 Observational Study of Nivolumab in Patients in Germany With Squamous Cell Carcinoma of the Head and Neck Progressing on or After Platinum-Based Therapy https://ClinicalTrials.gov/show/NCT03114163 Recruiting Bristol-Myers Squibb 2024-07-01
NCT03053661 Immune Response Evaluation to Curative Conventional Therapy https://ClinicalTrials.gov/show/NCT03053661 Active, not recruiting University of Ulm 2020-08-31
NCT02972216 Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy https://ClinicalTrials.gov/show/NCT02972216 Completed Yung Shin Pharm. Ind. Co., Ltd. 2016-10-31
NCT02881918 Anti-tumor Specific Immune Response in Head and Neck Cancers https://ClinicalTrials.gov/show/NCT02881918 Recruiting Central Hospital, Nancy, France 2021-03-31
NCT02778191 Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT02778191 Completed University Medical Center Groningen 2017-03-31
NCT02572778 Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer https://ClinicalTrials.gov/show/NCT02572778 Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2019-12-31
NCT03148665 Saliva-based Detection of CD44 https://ClinicalTrials.gov/show/NCT03148665 Active, not recruiting University of California, San Diego 2019-04-10
NCT01644786 The Head and Neck Tumor Biobank https://ClinicalTrials.gov/show/NCT01644786 Recruiting Maastricht Radiation Oncology 2022-08-31
NCT02543476 SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) https://ClinicalTrials.gov/show/NCT02543476 Completed AstraZeneca 2016-11-14
NCT02279459 Dual-Energy CT in Patients With Head and Neck Squamous Cell Carcinomas https://ClinicalTrials.gov/show/NCT02279459 Completed Ottawa Hospital Research Institute 2018-10-01
NCT02242916 State of the Art Photon Therapy Versus Particle Therapy for Recurrent Head & Neck Tumors; a Planning Study https://ClinicalTrials.gov/show/NCT02242916 Completed Maastricht Radiation Oncology 2015-10-31
NCT02139020 Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients https://ClinicalTrials.gov/show/NCT02139020 Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2023-01-31
NCT02003482 Prospective Trial of Serial CT Imaging for Evaluation of Dosimetric/Volumetric Changes During IMRT for Head/Neck Cancer https://ClinicalTrials.gov/show/NCT02003482 Completed University of Miami 2018-03-26
NCT01783158 Chromoendoscopy to Detect Early Synchronous Second Primary Esophageal Carcinoma https://ClinicalTrials.gov/show/NCT01783158 Completed University Hospital Ostrava 2012-11-30
NCT02024035 Protocole Advanced RadioTherapy ORL https://ClinicalTrials.gov/show/NCT02024035 Completed Centre Leon Berard 2012-03-31
NCT01358097 Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy https://ClinicalTrials.gov/show/NCT01358097 Completed Icahn School of Medicine at Mount Sinai 2013-09-30
NCT04260074 Epigenetic Changes in Head and Neck Cancer https://ClinicalTrials.gov/show/NCT04260074 Recruiting Aalborg University Hospital 2020-07-31
NCT04099290 Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT04099290 Recruiting UNC Lineberger Comprehensive Cancer Center 2020-09-30
NCT04086849 Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers https://ClinicalTrials.gov/show/NCT04086849 Recruiting Sunnybrook Health Sciences Centre 2024-12-30
NCT04050761 A Study of Nivolumab in Patients With Head and Neck Cancer. https://ClinicalTrials.gov/show/NCT04050761 Recruiting Bristol-Myers Squibb 2024-06-26
NCT04003025 Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC) https://ClinicalTrials.gov/show/NCT04003025 Recruiting Instituto do Cancer do Estado de São Paulo 2020-07-31
NCT03953443 Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC https://ClinicalTrials.gov/show/NCT03953443 Enrolling by invitation New Mexico Cancer Care Alliance 2025-12-31
NCT03938012 Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03938012 Recruiting National University Hospital, Singapore 2021-10-31
NCT03917537 WGA in Platinum-refractory HNSCC Underwent Nivolumab https://ClinicalTrials.gov/show/NCT03917537 Recruiting Chang Gung Memorial Hospital 2021-03-31
NCT03862066 Memory Phenotype in Oral Cancer https://ClinicalTrials.gov/show/NCT03862066 Recruiting Medical University of South Carolina 2020-12-01
NCT03712566 Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy https://ClinicalTrials.gov/show/NCT03712566 Active, not recruiting University Health Network, Toronto 2022-10-31
NCT03652142 Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03652142 Recruiting Attikon Hospital 2020-05-01
NCT01179360 Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) https://ClinicalTrials.gov/show/NCT01179360 Completed University Hospital, Antwerp 2015-12-31
NCT01080066 A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN) https://ClinicalTrials.gov/show/NCT01080066 Completed Merck KGaA, Darmstadt, Germany 2013-12-31
NCT04305366 MicroRNA Markers in Head and Neck Cancers https://ClinicalTrials.gov/show/NCT04305366 Recruiting University of Colorado, Denver 2022-02-28
NCT00620139 Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT00620139 Completed Memorial Sloan Kettering Cancer Center 2013-10-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03160495 Functional ImaGing of Heterogeneity in Head and Neck Tumors - Validation From Surgical Specimens https://ClinicalTrials.gov/show/NCT03160495 Completed Rigshospitalet, Denmark 2018-09-30